| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 08/27/2002 | US6440980 Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs |
| 08/27/2002 | US6440955 Anti-inflammatory agents |
| 08/27/2002 | US6440939 Thrombin inhibitors |
| 08/27/2002 | US6440938 Prevention and/or treatment of allergic conditions |
| 08/27/2002 | US6440937 Competitive inhibitors of trypsin-like serin proteases, especially thrombin and kininogenases such as kallikrein; thrombin inhibitors, anticoagulants, and antiinflammatory agents |
| 08/27/2002 | US6440936 Anti-protozoan methods and materials |
| 08/27/2002 | US6440935 Such as cecropins and sarcotoxins |
| 08/27/2002 | US6440934 Administering fibroblast growth factor-2 (fgf-2) alone or in combination with heparin |
| 08/27/2002 | US6440933 Compounds and method for the prevention and treatment of diabetic retinopathy |
| 08/27/2002 | US6440932 Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins |
| 08/27/2002 | US6440931 Conjugated linoleic acid in treatment and prophylaxis of diabetes |
| 08/27/2002 | US6440930 Protein formulations |
| 08/27/2002 | US6440929 Pulmonary delivery of active agents |
| 08/27/2002 | US6440928 Nerve growth factor |
| 08/27/2002 | US6440742 Recombinant AAV vector-based transduction system and use of same |
| 08/27/2002 | US6440739 Polypeptides; anticancer agent; wound healing agents |
| 08/27/2002 | US6440738 Polynucleotides |
| 08/27/2002 | US6440737 Antisense modulation of cellular apoptosis susceptibility gene expression |
| 08/27/2002 | US6440736 Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules |
| 08/27/2002 | US6440735 Dendritic cell vaccine containing telomerase reverse transcriptase for the treament of cancer |
| 08/27/2002 | US6440733 Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel |
| 08/27/2002 | US6440732 Checkpoint/repair genes involved with dna repair prior to replication; aging resistance; cancer therapy |
| 08/27/2002 | US6440729 Also for inhibiting tumors and metastasis; neovascularization |
| 08/27/2002 | US6440719 Method and reagent for inhibiting herpes simplex virus replication |
| 08/27/2002 | US6440702 For treatment of motor neuron diseases and muscle degenerative diseases; screening for therapeutic proteins by determining altered electrophoretic binding properties |
| 08/27/2002 | US6440701 Transferrin receptor genes of Moraxella |
| 08/27/2002 | US6440699 Prostate cancer susceptible CA7 CG04 gene |
| 08/27/2002 | US6440693 Given amino acid sequence; recombinant tumor necrosis factor (tnf)-binding protein useful in pharmaceuticals for inhibiting tnf |
| 08/27/2002 | US6440690 Peptides for the activation of the immune system in humans and animals |
| 08/27/2002 | US6440679 Dermatomyositis-specific auto-antigen |
| 08/27/2002 | US6440672 Compositions and methods for the inhibition of MUC-5 mucin gene expression |
| 08/27/2002 | US6440663 Renal cancer associated antigens and uses therefor |
| 08/27/2002 | US6440660 Oligonucleotide mediated reversal of drug resistance |
| 08/27/2002 | US6440656 Methods for the inhibition of respiratory syncytial virus transmission |
| 08/27/2002 | US6440465 Topical composition for the treatment of psoriasis and related skin disorders |
| 08/27/2002 | US6440463 Methods for fine powder formation |
| 08/27/2002 | US6440461 Drug delivery; biocompatibility, biodegradable |
| 08/27/2002 | US6440452 Therapeutic enclosures |
| 08/27/2002 | US6440445 Methods and compounds for treatment of abnormal uterine bleeding |
| 08/27/2002 | US6440427 Adhesives, sustained release, wound healing agents; blood-coagulation factor xiii; separate thrombin agent; viscosity enhancing polysaccharide or proteoglycan |
| 08/27/2002 | US6440423 Mutant enterotoxin effective as a non-toxic oral adjuvant |
| 08/27/2002 | US6440421 Treatment of bone disorders with adrenomedullin or adrenomedullin agonists |
| 08/27/2002 | US6440419 J chain or portion thereof linked to at least one enzyme inhibitor; specifically binds to basolateral factor; eradi-cation of metastatic or nonpolarized cells; lung, breast, colon, ovarian and prostate carcinoma and endometriosis |
| 08/27/2002 | US6440418 Variable light and heavy amino acid sequences encoded by nucleic acid sequences; seq id no:24, 25 and 26; rheumatoid arthritis, multiple sclerosis, diabetes, and systemic lupus erythematosus; graft versus host disease; gene therapy |
| 08/27/2002 | US6440414 Fibrolase and novel acting thrombolytic agents suitable for liquid frozen state or lyophilization storage; metallo-proteinase fibrinolytic agent of seq.id no: 1, zinc stabilizer, buffer and optionally a bulking agent |
| 08/27/2002 | US6440413 Selectively destroying subunit a without destroying subunit b of cholera toxin; enzyme with preponderance of exocellular proteinase produced by a culture of streptomyces fradiae; hyperviscosity of intestinal, bronchial and/or genital mucus |
| 08/27/2002 | US6440412 Purified forms of DNase |
| 08/27/2002 | US6440410 Normalizing cholesterol and blood pressure; administering natural antioxidant phytochemicals found in fruits and vegetables, including polyphenols, such as chlorogenic acid and ellagic acid, and an enzyme mixture |
| 08/27/2002 | US6440407 Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 (IL-3) multiple mutation polypeptides |
| 08/27/2002 | US6440392 Citric acid or salt stabilized solution; high bioavail-ability; treatment of conditions including osteoporosis, paget's disease and malignant hypercalcemia |
| 08/27/2002 | CA2224738C Use of ritonavir (abt-538) for improving the pharmacokinetics of drugs metabolized by cytochrome p450 in a method of treating aids |
| 08/27/2002 | CA2173939C Oligopeptides derived from c-reactive protein fragments |
| 08/27/2002 | CA2125888C Pharmaceutically active antioxidant containing composition and the method of its use to prevent and treat restenosis following angioplasty |
| 08/27/2002 | CA2125403C Novel tissue plasminogen activator variants |
| 08/27/2002 | CA2069929C Pharmaceutical composition having an endoproteolytic activity; a process for endoproteolytically processing (precursor) proteins and for the (micro)biological production of proteins |
| 08/27/2002 | CA2018592C Polypeptides and polypeptide analogues with inhibitory activity against human elastase |
| 08/26/2002 | CA2373363A1 Antitumor and antiviral medications and method for producing the same |
| 08/22/2002 | WO2002065129A2 Epitopic sequences for diagnosing infection by chlamydia trachomatis |
| 08/22/2002 | WO2002064841A1 Methods of using mammalian rnase h and compositions thereof |
| 08/22/2002 | WO2002064840A2 Methods for identifying compounds that inhibit or reduce ptp1b expression |
| 08/22/2002 | WO2002064836A1 Antisense modulation of protein phosphatase 2 catalytic subunit alpha expression |
| 08/22/2002 | WO2002064832A1 Method of examining allergic disease |
| 08/22/2002 | WO2002064827A2 Nucleic acids of the human abca12 gene, vectors containing such nucleic acids, and uses thereof |
| 08/22/2002 | WO2002064816A2 Multiple determinants for metabolic phenotypes |
| 08/22/2002 | WO2002064798A1 Dna sequences differentially expressed in tumour cell lines |
| 08/22/2002 | WO2002064797A2 Mitochondrial topoisomerase i |
| 08/22/2002 | WO2002064796A2 Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use |
| 08/22/2002 | WO2002064795A2 Putative human enzymes |
| 08/22/2002 | WO2002064793A2 G protein-coupled receptor-like proteins and nucleics acids encoding same |
| 08/22/2002 | WO2002064792A2 Molecules for disease detection and treatment |
| 08/22/2002 | WO2002064791A2 Proteins and nucleic acids encoding same |
| 08/22/2002 | WO2002064788A2 Compositions and methods relating to lung specific genes and proteins |
| 08/22/2002 | WO2002064784A2 Yeast strain of saccharomyces cerevisiae with functional expression of a glut transporter |
| 08/22/2002 | WO2002064783A2 Novel cofactors of the estrogen receptor beta and methods of use |
| 08/22/2002 | WO2002064781A2 Regulation of amyloid precursor protein expression by modification of abc transporter expression or activity |
| 08/22/2002 | WO2002064780A1 Dna sequences for human tumour suppressor genes |
| 08/22/2002 | WO2002064779A2 Peptide inhibitors of cellular proliferation |
| 08/22/2002 | WO2002064778A1 Rna showing neuron survival activity |
| 08/22/2002 | WO2002064777A2 Proteins 7b6 and 11b4 and dna sequences encoding the same |
| 08/22/2002 | WO2002064776A2 Signal transduction proteins 15b3, 15b3-1 and 15b3-2, and related dna sequences |
| 08/22/2002 | WO2002064775A1 Identification of genes involved in the tumourigenic process |
| 08/22/2002 | WO2002064769A1 Novel disease marker |
| 08/22/2002 | WO2002064766A2 Bax-responsive genes for drug target identification in yeast and fungi |
| 08/22/2002 | WO2002064742A2 Compounds effecting neuron remodeling and assays for same |
| 08/22/2002 | WO2002064741A2 Compositions and methods relating to breast specific genes and proteins |
| 08/22/2002 | WO2002064740A2 Cone snail peptides |
| 08/22/2002 | WO2002064739A2 A cytokine related structurally to il-17 |
| 08/22/2002 | WO2002064738A2 Modified target enzymes having catalytic triads and uses thereof |
| 08/22/2002 | WO2002064737A2 Antisense modulation of protein phosphatase 2 catalytic subunit beta expression |
| 08/22/2002 | WO2002064736A2 Protein-protein interactions |
| 08/22/2002 | WO2002064734A2 Identification of target-specific folding sites in peptides and proteins |
| 08/22/2002 | WO2002064733A2 Protein-protein interactions |
| 08/22/2002 | WO2002064732A2 POLYNUCLEOTIDE ENCODING A NOVEL HUMAN POTASSIUM CHANNEL ALPHA-SUBUNIT, K+alphaM1, AND VARIANTS THEREOF |
| 08/22/2002 | WO2002064731A2 Sequences involved in phenomena of tumour suppression, tumour reversion, apoptosis and/or virus resistance and their use as medicines |
| 08/22/2002 | WO2002064627A2 Crystallization of igf-1 |
| 08/22/2002 | WO2002064625A1 Matrix gene expression in chondrogenesis |
| 08/22/2002 | WO2002064623A1 Process for preparation of peptide derivatives |
| 08/22/2002 | WO2002064621A2 Histidine proline rich glycoprotein (hprg) as an anti-angiogenic and anti-tumor agent |
| 08/22/2002 | WO2002064620A2 Metal-binding compounds and uses therefor |
| 08/22/2002 | WO2002064619A2 Peptides that inhibit poly-glutamine aggregation |